Results 261 to 270 of about 219,440 (288)
Some of the next articles are maybe not open access.
Best Practice & Research Clinical Haematology, 2010
Epigenetic regulation is known to affect gene expression, and recent research shows that aberrant DNA methylation patterning may play a role in leukemogenesis. All leukemias display aberrant distribution of cytosine methylation, which is most notably distributed in specific and distinct signatures in acute myeloid leukemia (AML).
openaire +2 more sources
Epigenetic regulation is known to affect gene expression, and recent research shows that aberrant DNA methylation patterning may play a role in leukemogenesis. All leukemias display aberrant distribution of cytosine methylation, which is most notably distributed in specific and distinct signatures in acute myeloid leukemia (AML).
openaire +2 more sources
Clinical Lymphoma Myeloma and Leukemia, 2020 An ideal cell surface target for therapy in leukemia would be: tumor-specific (not expressed on normal cells) or at least enriched on tumor cells, necessary for tumor but not for normal cell survival, internalized efficiently (if the surface-targeted agent is conjugated to chemotherapy or a toxin molecule), and recycled rapidly to the cell surface ...
openaire +2 more sources
Blood, 2018
In this issue of Blood , Herrmann et al 1 have developed a novel checkpoint inhibitory T-cell–engaging (CiTE) antibody for acute myeloid leukemia (AML) by fusing the extracellular domain of programmed cell death protein 1 (PD-1 ex ) to a CD3 × CD33 bispecific T-cell engager (BiTE; see figure panels A-B). Incorporation of the PD-1 ex domain increased
Michael P. Rettig, John F. DiPersio
openaire +3 more sources
In this issue of Blood , Herrmann et al 1 have developed a novel checkpoint inhibitory T-cell–engaging (CiTE) antibody for acute myeloid leukemia (AML) by fusing the extracellular domain of programmed cell death protein 1 (PD-1 ex ) to a CD3 × CD33 bispecific T-cell engager (BiTE; see figure panels A-B). Incorporation of the PD-1 ex domain increased
Michael P. Rettig, John F. DiPersio
openaire +3 more sources
Blood, 2003
The introduction of the purine nucleoside analogs (PNAs) including fludarabine, pentostatin, and cladribine, either alone or in combination with other agents, has produced durable remissions and cures of patients with the chronic lymphoproliferative disorders chronic lymphocytic leukemia and ...
openaire +2 more sources
The introduction of the purine nucleoside analogs (PNAs) including fludarabine, pentostatin, and cladribine, either alone or in combination with other agents, has produced durable remissions and cures of patients with the chronic lymphoproliferative disorders chronic lymphocytic leukemia and ...
openaire +2 more sources
2014
FMS-like tyrosine kinase 3 (FLT3) receptor and its ligand play a significant role in human hematopoiesis and the proliferation and malignant transformation of primitive hematopoietic cells. FLT3 mutations are observed in approximately 30 % of adult AML, 1–3 % of adult B-ALL and 2–5 % of MDS patients.
Naval Daver, Farhad Ravandi
openaire +2 more sources
FMS-like tyrosine kinase 3 (FLT3) receptor and its ligand play a significant role in human hematopoiesis and the proliferation and malignant transformation of primitive hematopoietic cells. FLT3 mutations are observed in approximately 30 % of adult AML, 1–3 % of adult B-ALL and 2–5 % of MDS patients.
Naval Daver, Farhad Ravandi
openaire +2 more sources
Blood, 2010
In this issue of Blood , Gupta and colleagues report promising results using allo-SCT for patients with unfavorable cytogenetics in AML in CR1.[1][1] Their data show long-term outcomes for HLA well-matched URD are comparable with those from MSD transplantations. These findings suggest that the allo-
openaire +3 more sources
In this issue of Blood , Gupta and colleagues report promising results using allo-SCT for patients with unfavorable cytogenetics in AML in CR1.[1][1] Their data show long-term outcomes for HLA well-matched URD are comparable with those from MSD transplantations. These findings suggest that the allo-
openaire +3 more sources
Nature Medicine, 2018
The number, identity, and burden of mutations in clonal hematopoiesis are associated with the risk and timing of progression to acute myeloid leukemia.
Benjamin L. Ebert +6 more
openaire +3 more sources
The number, identity, and burden of mutations in clonal hematopoiesis are associated with the risk and timing of progression to acute myeloid leukemia.
Benjamin L. Ebert +6 more
openaire +3 more sources
Blood, 2014
In this issue of Blood , Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 7+3 in older patients with acute myeloid leukemia (AML).[1][1] ![Figure][2] Results of CPX ...
Judith E. Karp, Joshua F. Zeidner
openaire +3 more sources
In this issue of Blood , Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 7+3 in older patients with acute myeloid leukemia (AML).[1][1] ![Figure][2] Results of CPX ...
Judith E. Karp, Joshua F. Zeidner
openaire +3 more sources
Blood, 2016
In this issue of Blood , Dany et al demonstrate a critical role of the ceramide-regulated signaling pathway in inducing mitophagy to cause cell death and overcome drug resistance of acute myeloid leukemia (AML) cells carrying internal tandem duplication (ITD) of the Fms-like tyrosine kinase 3 (FLT3) gene.
openaire +3 more sources
In this issue of Blood , Dany et al demonstrate a critical role of the ceramide-regulated signaling pathway in inducing mitophagy to cause cell death and overcome drug resistance of acute myeloid leukemia (AML) cells carrying internal tandem duplication (ITD) of the Fms-like tyrosine kinase 3 (FLT3) gene.
openaire +3 more sources
AML Genomics for the Clinician
Seminars in Hematology, 2014Acute myeloid leukemia (AML) is a heterogeneous disease, characterized by frequent resistance to available chemotherapeutic agents. The basic therapy for patients with AML has changed little over the past 30 years. Improvements in outcome in recent decades in younger adult cohorts have generally been ascribed to better supportive care (ie, transfusion ...
Timothy A. Graubert, Richard Stone
openaire +3 more sources